But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
But camizestrant’s use could depend on uptake of monitoring – for now.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
Any hopes of differentiation could come down to side effects.
